Oppenheimer & Co’s Intellia Therapeutics NTLA Stock Holding History

Oppenheimer & Co’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.82M	Buy	107,453 +529	+0.5%	+$7.4K	0.02%	676
2026 Q1	$1.37M	Buy	106,924 +1,759	+2%	+$22.4K	0.02%	732
2025 Q4	$945K	Buy	105,165 +808	+0.8%	+$11.1K	0.01%	822
2025 Q3	$1.8M	Sell	104,357 -1,857	-2%	-$22.9K	0.02%	646
2025 Q2	$996K	Buy	106,214 +87,506	+468%	+$719K	0.01%	855
2025 Q1	$133K	Buy	18,708 +823	+5%	+$8.31K	﹤0.01%	1500
2024 Q4	$209K	Buy	+17,885	New	+$279K	﹤0.01%	1438
2023 Q4	–	Sell	-7,810	Closed	-$247K	–	1436
2023 Q3	$247K	Sell	7,810 -372	-5%	-$14.4K	0.01%	1199
2023 Q2	$334K	Buy	+8,182	New	+$332K	0.01%	1127
2021 Q4	–	Sell	-1,824	Closed	-$245K	–	1538
2021 Q3	$245K	Sell	1,824 -447	-20%	-$67.7K	﹤0.01%	1306
2021 Q2	$368K	Buy	+2,271	New	+$177K	0.01%	1153

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Oppenheimer & Co's NTLA Position: Q2 2026 in Review

Oppenheimer & Co increased its Intellia Therapeutics (NTLA) stake by 0.49% in Q2 2026, buying an estimated $7.4K and bringing the position to 107,453 shares worth $1.82M. The position accounts for 0.02% of the portfolio, ranked #676.

Oppenheimer & Co first reported a position in NTLA in Q2 2021 and has held it in 11 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Oppenheimer & Co held 107,453 shares of Intellia Therapeutics worth $1.82M as of Q2 2026.
Oppenheimer & Co bought 529 Intellia Therapeutics shares in Q2 2026, an estimated $7.4K.
Intellia Therapeutics made up 0.02% of Oppenheimer & Co's portfolio in Q2 2026, its #676 holding.
Oppenheimer & Co first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 11 quarters since.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.